Article Information
History
- August 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Lindsey Wang1,
- Nora D. Volkow2,
- Pamela B. Davis3,
- Nathan A. Berger1,
- David C. Kaelber4 and
- Rong Xu5,*
- 1Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- 2National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA
- 3Center for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- 4The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, OH, USA
- 5Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- ↵*Corresponding Author: Rong Xu, PhD, Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, Email: rxx{at}case.edu, Phone: 216-3680023
Posted August 06, 2022.
COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
